CLChanghong Li

Changhong Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Changhong Li has a total of 51 co-authors. Here are the top co-authors by number of shared publications:

  • Gang Liu

    State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine School of Public Health Xiamen University Xiamen China

    3 shared publications
  • Peiyu Wang

    State Key Laboratory of Vaccines for Infectious Diseases Center for Molecular Imaging and Translational Medicine Xiang An Biomedicine Laboratory National Innovation Platform for Industry‐Education Integration in Vaccine Research School of Public Health Xiamen University Xiamen China

    3 shared publications
  • Chengchao Chu

    State Key Laboratory of Vaccines for Infectious Diseases Xiang An Biomedicine Laboratory National Innovation Platform for Industry‐Education Integration in Vaccine Research Fujian Engineering Research Center of Molecular Theranostic Technology Center for Molecular Imaging and Translational Medicine School of Public Health Xiamen University Xiamen 361102 China

    2 shared publications
  • Dong Li

    State Key Laboratory of Vaccines for Infectious Diseases Xiang An Biomedicine Laboratory National Innovation Platform for Industry‐Education Integration in Vaccine Research Fujian Engineering Research Center of Molecular Theranostic Technology Center for Molecular Imaging and Translational Medicine School of Public Health Xiamen University Xiamen 361102 China

    2 shared publications
  • Erik Walter Thompson

    Centre for Genomics and Personalised Health and School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Australia

    2 shared publications
  • Jinyong Lin

    State Key Laboratory of Vaccines for Infectious Diseases Xiang An Biomedicine Laboratory National Innovation Platform for Industry‐Education Integration in Vaccine Research State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics Center for Molecular Imaging and Translational Medicine School of Public Health Xiamen University Xiamen 361102 China

    2 shared publications

Latest Publications

  • FlexiPlasma Microcatheter–Embolic Material (FPM‐EM) Platform: A Non‐Inflammatory Pyroptosis Strategy for Precision Hepatocellular Carcinoma Therapy

    by Changhong Li, Hongwei Cheng, Ziqi Zhuang, Fei Cao, Hui Liu, Liqian Zhao, Syed Faheem Askari Rizvi, Kanqi Wang, Liuyin Yang, Xiaowei Lu, et al.

    Hepatocellular carcinoma (HCC) remains a global challenge, with conventional locoregional therapies like transarterial chemoembolization (TACE) lacking tumor specificity and promoting metastasis and inflammation. Cold atmospheric plasma (CAP) offers a tumor‐selective ablation strategy but suffers from limited tissue penetration. To overcome this, the FlexiPlasma microcatheter (FPM) is developed, integrating flexible non‐metallic microtubes and ring‐shaped electrodes for precise CAP delivery to deep tumors. The optimized FPM‐generated CAP eliminates cytotoxic UV and ozone while inducing tumor‐specific pyroptosis via a ROS/Caspase‐8/GSDMC pathway. Gasdermin‐C (GSDMC) is highly expressed in liver tumors but absent in normal tissues, ensuring selective targeting with minimal inflammation. FPM is combined with embolic material (EM), PPP@CD hydrogel, enhancing injectability, tumor embolization, and sustained drug release. This FPM‐EM strategy potentiates antitumor immunity, particularly CD4+ and CD8+ T‐cell responses. These findings establish FPM‐EM as a safe, effective, and minimally invasive therapy for HCC, revealing a non‐inflammatory pyroptosis mechanism and broadening the potential of CAP‐based cancer treatments. The FPM‐EM combination offers promising new therapeutic options for HCC, addressing the limitations of TACE. Furthermore, the FPM‐EM platform can be extended to the interventional therapy of other tumors and adapted to incorporate various drugs and nano‐/micro‐materials, highlighting the strong potential for future clinical translation.


  • Next‐Generation Oral Ulcer Management: Integrating Cold Atmospheric Plasma (CAP) with Nanogel‐Based Pharmaceuticals for Inflammation Regulation

    by Yanfen Zheng, Ziqi Zhuang, Renwu Zhou, Luo Zheng, Changhong Li, Rusen Zhou, Yuting Gao, Liang Zhang, Yating Zheng, Liqian Zhao, et al.

    Oral ulcers, affecting 27.9% of adults, can lead to malnutrition and dehydration, especially in individuals with diabetes, cancer, viral infections, and autoimmune diseases. Existing treatments—including oral films, sprays, frosts, and powders—often fail to be effective due to rapid dilution and clearance in the moist oral environment. This study is the first to investigate the use of Cold Atmospheric Plasma (CAP) for treating oral ulcers and its underlying molecular mechanisms. A novel high‐bioavailability, mucoadhesive therapy combining handheld three dimensions (3D) multi‐microhole CAP is developed with a nanogel‐based pharmaceutical system containing glucose oxidase (GOx) and catalase (CAT), termed GCN. These results showed that both CAP alone and CAP combined with GCN significantly accelerate oral ulcer healing, modulate immune responses, and activate the Epidermal Growth Factor Receptor (EGFR) in acetic acid‐induced oral ulcers, outperforming untreated controls and the conventional medication, Watermelon Frost (WF). Furthermore, the CAP+GCN combination enhances therapeutic effects by promoting fibroblast generation. CAP pretreatment also enhances cell permeability and nanoparticle uptake, improving tissue adhesion. These findings are validated in primary Human Gingival Fibroblasts (HGF) and Human Periodontal Ligament Stem Cells (PDLSC) from healthy donors, as well as an oral ulcer model in rats, demonstrating superior biocompatibility and safety.


  • A review on reactive oxygen species (ROS)-inducing nanoparticles activated by uni- or multi-modal dynamic treatment for oncotherapy

    by Jinyong Lin, Dong Li, Changhong Li, Ziqi Zhuang, Chengchao Chu, Kostya (Ken) Ostrikov, Erik W. Thompson, Gang Liu, Peiyu Wang

    The multi-modal therapy has superior anti-tumor efficacy to the uni-modal using nanoparticles inducing reactive oxygen species (ROS). The multi-component nature of cold atmospheric plasma (CAP) enables multi-modal excitation with a single treatment.